SAN DIEGO–Cytori Therapeutics (NASDAQ:CYTX) has been informed that the United States Federal Court in the Central District of California upheld a June 2008 decision relating to U.S. patent number 6,777,231 (the ‘231 patent). The Court’s decision has no impact on Cytori’s products or clinical applications under development.

Cytori’s products do not practice the ‘231 patent. Cytori’s Celution® System yields an output comprising a diverse mixture of cells found in adipose tissue whereas the ‘231 patent covers a narrowly defined population of adipose derived adult stem cells in an environment substantially free of other cellular materials found in adipose tissue. The narrowly defined population of cells that are covered by the ‘231 patent require different isolation or processing techniques, which the Celution System, by design, does not perform.

In June 2008, Cytori was granted its first foundational U.S. patent for processing a heterogeneous or mixed population of adult stem and regenerative cells from adipose tissue. Cytori’s global portfolio now includes five issued U.S. patents, three allowed U.S. patents, 11 issued international patents and numerous pending patent applications that build on the Company’s core technology. All patents and pending patent applications within the Company’s global portfolio pertaining to the Celution System, including therapeutic uses for the mixed populations of adipose derived stem and regenerative cells that the Celution System produces, are owned by Cytori and are unaffected by this decision.

About Cytori

Cytori develops and globally commercializes regenerative medicine technologies, which provide real-time, point-of-care access to clinical grade regenerative cells. Our technology is incorporated into two product families. The Celution®-related products are sold throughout Europe and Asia primarily into the cosmetic and reconstructive surgery market and are under evaluation by the U.S. FDA. Our StemSource® products are sold globally for cell banking and research applications. We are also developing additional clinical uses of our technology for the treatment of multiple medical conditions, including cardiovascular disease, urinary tract disorders, and wound related conditions. To commercialize our technology, Cytori has partnered with global and regional leaders in healthcare such as Olympus Corporation, GE Healthcare, and Green Hospital Supply. www.cytoritx.com

Cautionary Statement Regarding Forward-Looking Statements

This press release includes forward-looking statements regarding events, trends and business prospects, which may affect our future operating results and financial position. Such statements are subject to risks and uncertainties that could cause our actual results and financial position to differ materially. Some of these risks and uncertainties include our history of operating losses, the need for further financing, inherent risk and uncertainty in the business operations of the company including intellectual property rights, regulatory uncertainties regarding the collection and results of, clinical data, dependence on third party performance, and other risks and uncertainties described under the “Risk Factors” in Cytori’s Securities and Exchange Commission Filings, including its annual report on Form 10-K for the year ended December 31, 2008. Cytori assumes no responsibility to update or revise any forward-looking statements contained in this press release to reflect events, trends or circumstances after the date of this press release.